Shi, V. Y., Ingram, J. R., Lev-Tov, H., Schneider-Burrus, S., Forman, S., Porter, M. L., . . . Szepietowski, J. C. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Adis, Springer Healthcare.
Chicago Style (17th ed.) CitationShi, Vivian Y., et al. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Adis, Springer Healthcare.
MLA (9th ed.) CitationShi, Vivian Y., et al. Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II. Adis, Springer Healthcare.
Warning: These citations may not always be 100% accurate.